Study evaluating, as first-line treatment of metastatic colorectal cancer, Bevacizumab +FOLFIRI followed by Bevacizumab + FOLFOX( or XELOX) or the reverse sequence Bevacizumab + FOLFOX (or XELOX) folloewed by Bevacizumab + FOLFIRI versus the standard Bevacizumab+ FOLFIRI
收藏NIAID Data Ecosystem2026-03-08 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2532389
下载链接
链接失效反馈官方服务：
资源简介：
Primary objectives: Progression free survival
创建时间：
2014-03-15
